Cellectis Analyst Ratings
Cellectis Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 224.32% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 04/05/2023 | 764.86% | Citigroup | $24 → $16 | Maintains | Buy |
| 03/13/2023 | 602.7% | Oppenheimer | $16 → $13 | Maintains | Outperform |
| 03/13/2023 | 224.32% | JMP Securities | → $6 | Reiterates | → Market Outperform |
| 01/19/2023 | 224.32% | JMP Securities | $11 → $6 | Maintains | Market Outperform |
| 05/24/2022 | 8.11% | Goldman Sachs | $3 → $2 | Maintains | Sell |
| 05/18/2022 | — | Baird | Upgrades | Neutral → Outperform | |
| 05/13/2022 | 278.38% | Barclays | $9 → $7 | Maintains | Overweight |
| 01/06/2022 | 764.86% | Wells Fargo | → $16 | Downgrades | Overweight → Equal-Weight |
| 11/30/2021 | 981.08% | JMP Securities | → $20 | Initiates Coverage On | → Market Outperform |
| 10/08/2021 | 440.54% | Baird | $39 → $10 | Downgrades | Outperform → Neutral |
| 04/28/2021 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 03/16/2021 | 2008.11% | Baird | $23 → $39 | Upgrades | Neutral → Outperform |
| 10/15/2020 | — | Baird | Downgrades | Outperform → Neutral | |
| 08/19/2020 | 1629.73% | Citigroup | $15 → $32 | Upgrades | Neutral → Buy |
| 07/07/2020 | 1035.14% | Baird | $28 → $21 | Maintains | Outperform |
| 03/06/2020 | 494.59% | Goldman Sachs | $15 → $11 | Downgrades | Neutral → Sell |
| 02/19/2020 | 2008.11% | BTIG | $37 → $39 | Maintains | Buy |
| 08/09/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 05/24/2019 | — | Citigroup | Assumes | → Neutral | |
| 03/14/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
| 12/19/2018 | 1251.35% | Goldman Sachs | → $25 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 08/07/2023 | 224.32% | JMP证券 | →$6 | 重申 | 市场表现优于→市场表现 |
| 04/05/2023 | 764.86% | 花旗集团 | $24→$16 | 维护 | 买 |
| 03/13/2023 | 602.7% | 奥本海默 | $16→$13 | 维护 | 跑赢大盘 |
| 03/13/2023 | 224.32% | JMP证券 | →$6 | 重申 | →市场跑赢大盘 |
| 2023年1月19日 | 224.32% | JMP证券 | $11→$6 | 维护 | 市场表现强于大盘 |
| 2022年05月24日 | 8.11% | 高盛 | $3→$2 | 维护 | 卖 |
| 2022/05/18 | - | 贝尔德 | 升级 | 中性→表现优异 | |
| 2022年05月13日 | 278.38% | 巴克莱 | $9→$7 | 维护 | 超重 |
| 01/06/2022 | 764.86% | 富国银行 | →$16 | 评级下调 | 超重→等重 |
| 2021年11月30日 | 981.08% | JMP证券 | →$20 | 开始承保 | →市场跑赢大盘 |
| 10/08/2021 | 440.54% | 贝尔德 | $39→$10 | 评级下调 | 跑赢→中性 |
| 04/28/2021 | - | 古根海姆 | 评级下调 | 购买→中性 | |
| 03/16/2021 | 2008.11% | 贝尔德 | $23→$39 | 升级 | 中性→表现优异 |
| 10/15/2020 | - | 贝尔德 | 评级下调 | 跑赢→中性 | |
| 2020年08月19日 | 1629.73% | 花旗集团 | $15→$32 | 升级 | 中性→购买 |
| 07/07/2020 | 1035.14% | 贝尔德 | $28→$21 | 维护 | 跑赢大盘 |
| 03/06/2020 | 494.59% | 高盛 | $15→$11 | 评级下调 | 中性→销售 |
| 02/19/2020 | 2008.11% | BTIG | $37→$39 | 维护 | 买 |
| 2019年08月09日 | - | BTIG | 开始承保 | →购买 | |
| 2019年05月24日 | - | 花旗集团 | 假设 | →中性 | |
| 2019/03/14 | - | 威廉·布莱尔 | 开始承保 | →跑赢大盘 | |
| 2018年12月19日 | 1251.35% | 高盛 | →$25 | 开始承保 | →中性 |
What is the target price for Cellectis (CLLS)?
Cellectis(CLLS)的目标价是多少？
The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on August 7, 2023. The analyst firm set a price target for $6.00 expecting CLLS to rise to within 12 months (a possible 224.32% upside). 5 analyst firms have reported ratings in the last year.
纳斯达克(JMP Securities)于2023年8月7日报告了Cellectis(JMP Securities：CLLS)的最新目标价。这家分析公司将目标价定为6美元，预计CLL将在12个月内升至(可能上涨224.32%)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Cellectis (CLLS)?
Cellectis(CLLS)的最新分析师评级是多少？
The latest analyst rating for Cellectis (NASDAQ: CLLS) was provided by JMP Securities, and Cellectis reiterated their market outperform rating.
纳斯达克(JMP Securities)对Cellectis的最新分析师评级为CLLS，Cellectis重申了其表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for Cellectis (CLLS)?
Cellectis(CLLS)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cellectis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cellectis was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Cellectis的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Cellectis的上一次评级是在2023年8月7日提交的，所以你应该预计下一次评级将在2024年8月7日左右的某个时候提供。
Is the Analyst Rating Cellectis (CLLS) correct?
分析师评级Cellectis(CLLS)正确吗？
While ratings are subjective and will change, the latest Cellectis (CLLS) rating was a reiterated with a price target of $0.00 to $6.00. The current price Cellectis (CLLS) is trading at is $1.85, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Cellectis(CLLS)评级被重申，目标价在0.00美元至6.00美元之间。Cellectis(CLLS)目前的交易价格为1.85美元，在分析师的预测范围内。
译文内容由第三方软件翻译。